Fresenius Medical Care (NYSE: FMS) reported Q4 EPS of EUR0.23, EUR0.26 worse than the analyst estimate of EUR0.49. Revenue for the quarter came in at EUR5.09 billion versus the consensus estimate of EUR6.02 billion.

Outlook 2025

In 2025, Fresenius Medical Care expects revenue growth to be positive to a low-single digit percent rate compared to prior year.

The Company expects operating income to grow by a high-teens to high-twenties percent rate compared to prior year.

The expected growth rates for 2025 are at constant currency, excluding special items2 in operating income. The 2024 basis for the revenue outlook is EUR 19,336 million and for the operating income outlook is EUR 1,797 million.

For earnings history and earnings-related data on Fresenius Medical Care (FMS) click here.